EP3589373A4 - COMPOSITIONS AND PROCEDURES FOR IMMUNOTHERAPY - Google Patents

COMPOSITIONS AND PROCEDURES FOR IMMUNOTHERAPY Download PDF

Info

Publication number
EP3589373A4
EP3589373A4 EP18761512.5A EP18761512A EP3589373A4 EP 3589373 A4 EP3589373 A4 EP 3589373A4 EP 18761512 A EP18761512 A EP 18761512A EP 3589373 A4 EP3589373 A4 EP 3589373A4
Authority
EP
European Patent Office
Prior art keywords
immunotherapy
procedures
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP18761512.5A
Other languages
German (de)
French (fr)
Other versions
EP3589373A1 (en
Inventor
Vipin Suri
Kutlu Goksu ELPEK
Michelle Lynn OLS
Brian DOLINSKI
Nicole KOSMIDER
Scott Francis HELLER
Abhishek KULKARNI
Mara Christine INNISS
Dan Jun LI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Obsidian Therapeutics Inc
Original Assignee
Obsidian Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Obsidian Therapeutics Inc filed Critical Obsidian Therapeutics Inc
Publication of EP3589373A1 publication Critical patent/EP3589373A1/en
Publication of EP3589373A4 publication Critical patent/EP3589373A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4252—Phosphatases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4256—Tumor associated carbohydrates
    • A61K40/4258—Gangliosides, e.g. GM2, GD2 or GD3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0026—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on CH-NH groups of donors (1.5)
    • C12N9/0028—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on CH-NH groups of donors (1.5) with NAD or NADP as acceptor (1.5.1)
    • C12N9/003—Dihydrofolate reductase [DHFR] (1.5.1.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0055—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/485—Exopeptidases (3.4.11-3.4.19)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472—Cysteine endopeptidases (3.4.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y105/00—Oxidoreductases acting on the CH-NH group of donors (1.5)
    • C12Y105/01—Oxidoreductases acting on the CH-NH group of donors (1.5) with NAD+ or NADP+ as acceptor (1.5.1)
    • C12Y105/01003—Dihydrofolate reductase (1.5.1.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04053—3',5'-Cyclic-AMP phosphodiesterase (3.1.4.53)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/14—Dipeptidyl-peptidases and tripeptidyl-peptidases (3.4.14)
    • C12Y304/14005—Dipeptidyl-peptidase IV (3.4.14.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/01—Hydro-lyases (4.2.1)
    • C12Y402/01001—Carbonate dehydratase (4.2.1.1), i.e. carbonic anhydrase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y502/00—Cis-trans-isomerases (5.2)
    • C12Y502/01—Cis-trans-Isomerases (5.2.1)
    • C12Y502/01008—Peptidylprolyl isomerase (5.2.1.8), i.e. cyclophilin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/82—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by targeting or presenting multiple antigens
    • A61K2239/29—Multispecific CARs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EP18761512.5A 2017-03-03 2018-03-02 COMPOSITIONS AND PROCEDURES FOR IMMUNOTHERAPY Pending EP3589373A4 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762466601P 2017-03-03 2017-03-03
US201762484063P 2017-04-11 2017-04-11
US201762542402P 2017-08-08 2017-08-08
PCT/US2018/020704 WO2018160993A1 (en) 2017-03-03 2018-03-02 Compositions and methods for immunotherapy

Publications (2)

Publication Number Publication Date
EP3589373A1 EP3589373A1 (en) 2020-01-08
EP3589373A4 true EP3589373A4 (en) 2020-12-23

Family

ID=63370245

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18761512.5A Pending EP3589373A4 (en) 2017-03-03 2018-03-02 COMPOSITIONS AND PROCEDURES FOR IMMUNOTHERAPY

Country Status (6)

Country Link
EP (1) EP3589373A4 (en)
JP (3) JP7660343B2 (en)
CN (1) CN110913954A (en)
AU (1) AU2018226857B2 (en)
CA (1) CA3055200A1 (en)
WO (1) WO2018160993A1 (en)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
CN105939767B (en) 2014-01-08 2018-04-06 弗洛设计声能学公司 Sound electrophoretic apparatus with alliteration electrophoresis chamber
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
EP4317422A3 (en) 2017-04-13 2024-05-01 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
CA3067211A1 (en) 2017-06-12 2018-12-20 Obsidian Therapeutics, Inc. Pde5 compositions and methods for immunotherapy
US11891634B2 (en) 2017-06-23 2024-02-06 The Board Of Trustees Of The Leland Stanford Junior University PDE5A destabilizing domains
EP3725092A4 (en) 2017-12-14 2021-09-22 FloDesign Sonics, Inc. Acoustic transducer drive and controller
EP3850004A4 (en) * 2018-09-13 2022-09-07 Nkarta, Inc. NATURAL KILLER CELL COMPOSITIONS AND IMMUNOTHERAPY METHODS FOR TREATING TUMORS
US20200101076A1 (en) * 2018-09-28 2020-04-02 Harrow Ip, Llc Pharmaceutical compositions for prevention or treatment of cytokine release syndrome
US11419898B2 (en) 2018-10-17 2022-08-23 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
US10993967B2 (en) 2018-10-17 2021-05-04 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
WO2020081841A1 (en) * 2018-10-19 2020-04-23 Regents Of The University Of Minnesota Nk engager molecules and methods of use thereof
EP3893901A4 (en) * 2018-12-11 2023-01-04 The Regents of the University of California Compositions and methods for immunotherapies
CN116479022A (en) * 2018-12-12 2023-07-25 中南大学 A kind of recombinant CAR19-IL24 gene, lentiviral vector, CAR19-IL24-T cell and application
CN113811549A (en) 2019-02-21 2021-12-17 Xencor股份有限公司 Untargeted and targeted IL-10 FC fusion proteins
AU2020232691B2 (en) 2019-03-05 2023-06-29 Nkarta, Inc. CD19-directed chimeric antigen receptors and uses thereof in immunotherapy
SG11202109225WA (en) 2019-03-08 2021-09-29 Obsidian Therapeutics Inc Cd40l compositions and methods for tunable regulation
CN113966397A (en) * 2019-03-08 2022-01-21 黑曜石疗法公司 Human Carbonic Anhydrase 2 Compositions and Methods for Tunable Regulation
CN114007665B (en) * 2019-04-11 2024-11-12 因柯利尔疗法公司 Method for improving cerebrospinal fluid and its device and system
US20220378824A1 (en) * 2019-04-30 2022-12-01 Myeloid Therapeutics, Inc. Engineered chimeric fusion protein compositions and methods of use thereof
CA3140668A1 (en) * 2019-06-12 2020-12-17 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
US20240218357A1 (en) * 2019-06-21 2024-07-04 Kernal Biologics, Inc. Engineered oncoselective protein expression
US20230092895A1 (en) 2019-08-30 2023-03-23 Obsidian Therapeutics, Inc. Tandem cd19 car-based compositions and methods for immunotherapy
JP7692897B2 (en) 2019-09-10 2025-06-16 オブシディアン セラピューティクス， インコーポレイテッド CA2-IL15 Fusion Protein for Regulatable Regulation
US20230399390A1 (en) * 2019-10-24 2023-12-14 Novago Therapeutics Ag Novel anti-nogo-a antibodies
WO2021202581A1 (en) * 2020-03-30 2021-10-07 WUGEN, Inc. Engineered immune cells for adoptive cell therapy
EP4130027A4 (en) * 2020-03-31 2024-08-14 Hanmi Pharm. Co., Ltd. Novel immunoactive interleukin 2 analog
WO2021209049A1 (en) * 2020-04-16 2021-10-21 南通壹宸生物医药科技有限公司 Pd-1 mutant polypeptide, and preparation therefor and use thereof
WO2022060806A1 (en) * 2020-09-16 2022-03-24 Obsidian Therapeutics, Inc. Compositions and methods for expression of anti-bcma chimeric antigen receptors with small molecule-regulated il15 in t cells
KR20230107804A (en) 2020-09-29 2023-07-18 엔클리어 테라피스, 인크. Subarachnoid fluid management method and system
US12012441B2 (en) 2020-10-26 2024-06-18 Neptune Biosciences Llc Engineered human IL-21 cytokines and methods for using the same
CN113307869B (en) * 2020-10-30 2023-01-06 上海洛启生物医药技术有限公司 anti-IL 5 nano antibody and application thereof
CN117642173A (en) * 2020-12-07 2024-03-01 华东理工大学 Methods and kits for inducing immune tolerance to gene delivery targeting agents
EP4259782A1 (en) * 2020-12-14 2023-10-18 Allogene Therapeutics, Inc. Methods and reagents for characterizing car t cells for therapies
CN114685683B (en) * 2020-12-31 2025-07-08 博生吉医药科技(苏州)有限公司 GD 2-targeted CAR-T cell, and preparation and application thereof
CN112795543B (en) * 2021-02-04 2022-09-27 华中农业大学 Hybridoma cell line and its secreted anti-grass carp IL-15Rα monoclonal antibody and its application
WO2022228492A1 (en) * 2021-04-29 2022-11-03 苏州沙砾生物科技有限公司 Modified tumor-infiltrating lymphocyte and use thereof
CN117915932A (en) * 2021-07-28 2024-04-19 预见疗法有限公司 Universal receptor immune cell therapy
CN116082515A (en) * 2021-11-08 2023-05-09 浙江海隆生物科技有限公司 A foot-and-mouth disease virus capsid fusion protein soluble expressed in Escherichia coli and its preparation method
CN114317385B (en) * 2021-11-11 2024-02-13 元本(珠海横琴)生物科技有限公司 Fermentation medium and fermentation process for promoting secretion and expression of HER2 affibody protein
JP2025538155A (en) * 2022-11-04 2025-11-26 ティー － マキシマム ファーマシューティカル （スーチョウ） カンパニー、リミテッド Universal CAR-T cells targeting B7H3, and methods for producing and using the same
CN115558641B (en) * 2022-11-14 2023-05-12 四川新生命干细胞科技股份有限公司 High-purity effector immune cell population, culture method, reagent composition and application thereof
CN115645515A (en) * 2022-12-28 2023-01-31 北京圣美细胞生命科学工程研究院有限公司 Tumor treatment composition and application, pharmaceutical composition and cell growth inhibition method
WO2024140980A1 (en) * 2022-12-30 2024-07-04 上药生物治疗（香港）有限公司 Cell expressing chemokine receptor and use thereof
US20250032615A1 (en) * 2023-03-10 2025-01-30 The Regents Of The University Of Colorado, A Body Corporate Anti-cd56 and anti-cd99 logic gated chimeric antigen receptors for the treatment of cancer
WO2024189583A1 (en) 2023-03-15 2024-09-19 Kyoto Prefectural Public University Corporation Peptide expression constructs and uses thereof
WO2025160432A1 (en) * 2024-01-26 2025-07-31 Poseida Therapeutics, Inc. Methods and compositions for enhancing in vivo persistence and potency of cell therapy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8173792B2 (en) * 2007-02-09 2012-05-08 The Board Of Trustees Of The Leland Stanford Junior University Method for regulating protein function in cells using synthetic small molecules
US20140010791A1 (en) * 2008-05-07 2014-01-09 The Board Of Trustees Of The Leland Stanford Junior University Methods for regulating protein function in cells in vivo using synthetic small molecules

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040141972A1 (en) * 1997-11-21 2004-07-22 Genentech, Inc. Compounds, compositions and methods for the treatment of diseases characterized by A-33 related antigens
AU2006241206B2 (en) * 2005-04-26 2011-06-09 Eisai R&D Management Co., Ltd. Compositions and methods for cancer immunotherapy
US20080057066A1 (en) * 2006-02-13 2008-03-06 Vishva Dixit Methods and compositions for targeting relt
WO2011146568A1 (en) * 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
CN105612180B (en) * 2013-07-19 2019-11-12 弗拉芒区生物技术研究所 Targeted modified IL-1 family members
WO2017180587A2 (en) * 2016-04-11 2017-10-19 Obsidian Therapeutics, Inc. Regulated biocircuit systems

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8173792B2 (en) * 2007-02-09 2012-05-08 The Board Of Trustees Of The Leland Stanford Junior University Method for regulating protein function in cells using synthetic small molecules
US20140010791A1 (en) * 2008-05-07 2014-01-09 The Board Of Trustees Of The Leland Stanford Junior University Methods for regulating protein function in cells in vivo using synthetic small molecules

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ALEXANDRE JUILLERAT ET AL: "Design of chimeric antigen receptors with integrated controllable transient functions", SCIENTIFIC REPORTS, vol. 6, 11 January 2016 (2016-01-11), pages 18950, XP055271820, DOI: 10.1038/srep18950 *
See also references of WO2018160993A1 *

Also Published As

Publication number Publication date
JP2020511528A (en) 2020-04-16
AU2018226857B2 (en) 2025-01-02
JP2021088598A (en) 2021-06-10
CN110913954A (en) 2020-03-24
JP7660343B2 (en) 2025-04-11
JP2025013868A (en) 2025-01-28
EP3589373A1 (en) 2020-01-08
WO2018160993A1 (en) 2018-09-07
AU2018226857A1 (en) 2019-09-19
CA3055200A1 (en) 2018-09-07

Similar Documents

Publication Publication Date Title
EP3589373A4 (en) COMPOSITIONS AND PROCEDURES FOR IMMUNOTHERAPY
EP3493827A4 (en) COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY
EP3718370A4 (en) METHODS AND RELATED DEVICES FOR MULTICONNECTIVITY
EP3573447A4 (en) COMPOSITIONS AND RELATED PROCEDURES FOR AGRICULTURE
EP3487990A4 (en) T-CELL COMPOSITIONS FOR IMMUNOTHERAPY
EP3694530A4 (en) OLIGONUCLEOTIDE COMPOSITIONS AND METHOD FOR THEREFORE
EP3664815A4 (en) OLIGONUCLEOTIDE COMPOSITIONS AND METHOD FOR THEREFORE
EP3638289A4 (en) PDE5 COMPOSITIONS AND PROCEDURES FOR IMMUNOTHERAPY
EP3589295A4 (en) COMPOSITIONS AND PROCEDURES FOR CAR-T CELL THERAPY
EP3823673A4 (en) ANTI-CD112R COMPOSITIONS AND METHODS
EP3658179C0 (en) METHODS AND COMPOSITIONS FOR HETEROLOGICAL REPRNA IMMUNIZATIONS
EP3362103C0 (en) COMPOSITIONS AND METHODS FOR VIRAL CANCER NEOPITOPES
EP3523437A4 (en) OLIGONUCLEOTIDE COMPOSITIONS AND METHOD THEREFOR
EP3484508A4 (en) COMPOSITIONS AND METHODS FOR ALPHAVIRUS VACCINATION
EP3573642A4 (en) COMPOSITIONS AND RELATED PROCEDURES FOR AGRICULTURE
EP3716990A4 (en) COMPOSITIONS AND PROCEDURES FOR NEUROLOGICAL DISEASES
EP3603181A4 (en) CONDITION FOR REACHING
EP3827846C0 (en) COMPOSITIONS, COMBINATIONS AND RELATED METHODS FOR PHOTOIMMUNOTHERAPY
EP3217046C0 (en) ORDER AND RELATED PROCEDURES
IL248235A0 (en) Method and compositions for cellular immunotherapy
EP3464349A4 (en) COMPOSITIONS AND PROCEDURES FOR STAPHYLOCOCCLE LEUKOTOXIN ANTIBODIES
EP3484509A4 (en) COMPOSITIONS AND METHODS FOR FLAVIVIRUS VACCINATION
EP3706558A4 (en) COMPOSITIONS AND PROCEDURES FOR AQUACULTURE
EP3826468A4 (en) COMPOSITIONS AND RELATED PROCEDURES FOR AGRICULTURE
EP3230302C0 (en) CARRIER MOLECULE COMPOSITIONS AND RELATED METHODS

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20191001

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RIN1 Information on inventor provided before grant (corrected)

Inventor name: KOSMIDER, NICOLE

Inventor name: SURI, VIPIN

Inventor name: DOLINSKI, BRIAN

Inventor name: ELPEK, KUTLU GOKSU

Inventor name: OLS, MICHELLE LYNN

Inventor name: KULKARNI, ABHISHEK

Inventor name: LI, DAN JUN

Inventor name: HELLER, SCOTT FRANCIS

Inventor name: INNISS, MARA CHRISTINE

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20201125

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 9/64 20060101ALI20201119BHEP

Ipc: C12N 9/90 20060101ALI20201119BHEP

Ipc: C07K 14/47 20060101ALI20201119BHEP

Ipc: C12N 9/48 20060101ALI20201119BHEP

Ipc: C07K 14/705 20060101ALI20201119BHEP

Ipc: A61P 35/00 20060101ALI20201119BHEP

Ipc: C12N 9/16 20060101ALI20201119BHEP

Ipc: C12N 9/88 20060101ALI20201119BHEP

Ipc: C07K 14/55 20060101ALI20201119BHEP

Ipc: A61K 39/39 20060101ALI20201119BHEP

Ipc: A61K 35/00 20060101ALI20201119BHEP

Ipc: C12N 15/62 20060101ALI20201119BHEP

Ipc: C07K 14/54 20060101ALI20201119BHEP

Ipc: C12N 9/02 20060101ALI20201119BHEP

Ipc: A61P 37/02 20060101AFI20201119BHEP

Ipc: C12N 9/06 20060101ALI20201119BHEP

Ipc: A61K 39/00 20060101ALI20201119BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20241106